Neurocrine details Phase 2 results for depression drug news2025-09-23T15:24:29+00:00September 23rd, 2025|Endpoints News|
Bristol Myers said its next-gen multiple myeloma drug cut rates of detectable cancer. Will it get FDA approval?news2025-09-23T15:16:15+00:00September 23rd, 2025|Endpoints News|
Pfizer’s future lead obesity candidate from Metsera needs to match Zepboundnews2025-09-23T10:51:20+00:00September 23rd, 2025|Endpoints News|
Ionis says RNA drug for rare brain disorder succeeded pivotal trial, plans to ask for FDA approvalnews2025-09-22T15:23:36+00:00September 22nd, 2025|Endpoints News|
MBX Biosciences shares Phase 2 hypoparathyroidism data as it seeks to compete with Ascendis, AstraZenecanews2025-09-22T11:00:01+00:00September 22nd, 2025|Endpoints News|
Roche declares Phase 3 win for SERD in broad breast cancer population that eluded competitorsnews2025-09-22T10:29:20+00:00September 22nd, 2025|Endpoints News|
ACIP recommends that people consult a provider before getting Covid shotsnews2025-09-19T19:54:08+00:00September 19th, 2025|Endpoints News|
Regeneron’s Lynozyfic yields 100% response rate in small smoldering multiple myeloma studynews2025-09-19T17:15:16+00:00September 19th, 2025|Endpoints News|
Regeneron posts update on its muscle-sparing approach, a new quadruple agonist emerges at #EASD25news2025-09-19T11:20:28+00:00September 19th, 2025|Endpoints News|
ACIP votes to not recommend combined MMRV shot for kids under 4news2025-09-18T13:44:53+00:00September 18th, 2025|Endpoints News|
